Veravas is classified as operating in the In-Vitro Diagnostic Substance Manufacturing industry, NAICS Code 325413.
Investor Activity
Veravas has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
April 1, 2024
138
78%
$26 MM
Complete list of funding rounds and total amounts in the Company Report
Market Share of Veravas's Largest Competitors
A competitive analysis shows these companies are in the same general field as Veravas, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Veravas.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Veravas and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.